Home Use Study of Targeted Mechanical Stimulation for Tremor Relief
NCT ID: NCT07078422
Last Updated: 2025-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
80 participants
INTERVENTIONAL
2025-01-01
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Alpha phase: Two remote study visits and an in-home period to gather device usability data on the alpha system. The at home period for this phase will be 2 weeks. This phase will be used to confirm that the device and labeling are suitable for in-home use.
2. Beta Phase B1: Beta Phase B1 will be conducted using the beta devices for two in-person or remote, 60 to 90-minute, visits. This phase will be used to assess design changes between alpha and beta versions.
3. Beta Phase B2: Seven remote visits and in-home usage to gather usability and efficacy data on the beta system in-home. Beta Phase B2 will be conducted using the beta devices for 12 weeks. This phase will be used to assess design changes between alpha and beta versions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuromodulation Strategies for Treatment-Resistant Essential Tremor Using Chronos™ DBS
NCT07302867
Chronic Versus Intermittent Deep Brain Stimulation for Essential Tremor
NCT01334814
Sensory-specific Peripheral Stimulation for Tremor Management
NCT04501133
Wearable Sensor for Responsive DBS for ET
NCT03051178
Electromagnetic Tracking to Measure Tremor
NCT02641366
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Oder of assessment begins with TETRAS and ends with ADLs
Encora Pulse
The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.
This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration.
B
Order of assessment begins with ADLs and ends with TETRAs
Encora Pulse
The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.
This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration.
C
Order of assessment begins with TETRAS and ends with ADLs, but both are administered backwards
Encora Pulse
The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.
This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration.
D
Order of assessment begins with ADLs and ends with TETRAs, but both are administered backwards
Encora Pulse
The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.
This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Encora Pulse
The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.
This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mentally competent to understand and able to perform written, informed consent to participate in the study
* A diagnosis of either ET or PD as determined by clinical history
* Moderate to severe upper limb tremor
* Age 18 years or older, able to comply with all study procedures and capable of providing informed consent
* Mentally competent to understand and able to perform written, informed consent to participate in the study
* For ET subjects, a diagnosis of essential tremor defined as definite or probable ET based on TRIG criteria
* For PD subjects, a diagnosis of Parkinson's disease by a Movement Disorder Specialist
* For ET subjects, at least one hand exhibiting tremor \> 2 as assessed by the Essential Tremor Rating Assessment Scale (TETRAS) finger to nose task, duck wing task, OR Archimedes Spiral completed during the Screening visit
* For PD subjects, a score \> 2 on at least one of MDS-UPDRS items 3.15, 3.16 or 3.17 At the Screening Visit, a score of \> 3 on one of the following subject-assessed items of the Bain \& Findley Activities of Daily Living Scale (BF-ADL): Use a spoon to drink soup, Hold a cup of tea, Do up buttons, Do up a zipper, Write a letter
* Stable medications for at least 30 days prior to enrollment and the ability to maintain tremor medications throughout the duration of study participation
* For PD subjects, able to participate in visits in a practically defined OFF state (withdrawal from all tremor medication for 12 hours prior to study visits)
* A wrist circumference of 6.0 - 8.1 inches
Exclusion Criteria
* Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site
* History of psoriasis, eczema or atopic dermatitis at the stimulation site
* History of peripheral neuropathy in the upper limbs, including carpal tunnel syndrome and diabetic neuropathy
* Participant unable to communicate with sponsor/investigator and staff
* Any other medical conditions or physical or mental impairments that in the sponsor/investigator's opinion would render the subject unsuitable as a candidate for the study.
* Pregnant women
* Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site
* History of psoriasis, eczema or atopic dermatitis at the stimulation site
* History of peripheral neuropathy in the upper limbs, including carpal tunnel syndrome and -diabetic neuropathy
* Participant unable to communicate with sponsor/investigator and staff
* Any other medical conditions or physical or mental impairments that in the sponsor/investigator's opinion would render the subject unsuitable as a candidate for the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Encora, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ann Marie Murray, MD
Role: PRINCIPAL_INVESTIGATOR
WVU Comprehensive Movement Disorder Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Encora Therapeutics
Cambridge, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20232333
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.